phenoxybenzamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2136 59-96-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phenoxybenzamine
  • phenoxybenzamine hydrochloride
  • dibenylin
  • dibenyline
  • dibenzyline
  • phenoxybenzamine HCl
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
  • Molecular weight: 303.83
  • Formula: C18H22ClNO
  • CLOGP: 4.92
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -4.47
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.82 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Jan. 26, 1953 FDA COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC C04AX02 CARDIOVASCULAR SYSTEM
PERIPHERAL VASODILATORS
PERIPHERAL VASODILATORS
Other peripheral vasodilators
MeSH PA D018663 Adrenergic Agents
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pheochromocytoma indication 302835009
Acute cerebrovascular insufficiency contraindication 29322000
Low blood pressure contraindication 45007003
Lower respiratory tract infection contraindication 50417007
Kidney disease contraindication 90708001 DOID:557
Disorder of coronary artery contraindication 414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR ANTAGONIST Ki 8.46 PDSP CHEMBL
Alpha-1A adrenergic receptor GPCR ANTAGONIST IC50 7.27 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR ANTAGONIST IC50 6.28 WOMBAT-PK CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.35 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.82 CHEMBL
Dopamine receptor GPCR Ki 6.92 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 8.74 CHEMBL

External reference:

IDSource
4019890 VUID
N0000147975 NUI
C0031441 UMLSCUI
D00507 KEGG_DRUG
0TTZ664R7Z UNII
608 INN_ID
74771007 SNOMEDCT_US
4019890 VANDF
8149 RXNORM
372838003 SNOMEDCT_US
d00734 MMSL
004738 NDDF
CHEBI:8077 CHEBI
CHEMBL753 ChEMBL_ID
DB00925 DRUGBANK_ID
CHEMBL1200787 ChEMBL_ID
63-92-3 SECONDARY_CAS_RN
4768 PUBCHEM_CID
D010643 MESH_DESCRIPTOR_UI
7268 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Phenoxybenzamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0349 CAPSULE 10 mg ORAL ANDA 12 sections
Phenoxybenzamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49884-038 CAPSULE 10 mg ORAL ANDA 14 sections
Dibenzyline HUMAN PRESCRIPTION DRUG LABEL 1 59212-001 CAPSULE 10 mg ORAL NDA 14 sections
Phenoxybenzamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 66993-066 CAPSULE 10 mg ORAL NDA AUTHORIZED GENERIC 14 sections